Seattle-based biotech A-Alpha Bio has raised $22.4 million in what it’s calling a Series A2 round.
With the funding, announced Tuesday, A-Alpha wants to develop its internal treatment pipeline, which co-founder and CEO David Younger said is primarily focused on oncology. The company also plans to develop its machine learning and protein interaction data technology.
“Going through the motions of discovering our own therapies and taking those through pre-clinical, obviously that’s quite resource-intensive,” Younger said. “This funding will allow us to really accelerate some of those programs.”